Constipation News and Research

Latest Constipation News and Research

Added benefit of lurasidone drug not proven for schizophrenia

The drug lurasidone (trade name Latuda) has been available since November 2014 for the treatment of adults with schizophrenia. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

8 Feb 2015

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

2 Feb 2015

Temple University Hospital participating in trial to test vibrating capsule for chronic constipation treatment

Chronic constipation is a common problem that affects approximately 15 percent of the U.S. population, according to the American Gastroenterological Association. It can be painful and lead to a reduction in a patient's quality of life. Temple University Hospital is the only hospital in the Philadelphia region participating in a nationwide clinical trial to test an innovative, vibrating capsule for patients with chronic constipation.

31 Jan 2015

Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Shire plc announced today that the U.S. Food and Drug Administration approved Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults, shown to significantly reduce the mean number of binge days per week.

30 Jan 2015

Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms tend to appear in specific clusters in patients with Parkinson’s disease and often predate the onset of motor symptoms, research shows.

16 Jan 2015

Disturbed gut microbiome linked to Parkinson’s disease

Research suggests that the intestinal microbiome may be altered in patients with Parkinson’s disease, with some alterations being specific to the motor subtype.

16 Jan 2015

New research sheds light on the role of Sox10 protein in Hirschsprung's disease patients

Defects in the protein Sox10, a transcription factor that regulates gene expression, may play a role in the development of post-operative GI dysfunction in Hirschsprung's disease patients, according to new research published in Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

16 Jan 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

31 Dec 2014

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.

30 Dec 2014

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.

25 Dec 2014

Keryx Biopharmaceuticals supplies AURYXIA tablets to wholesalers in US

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") today announced it has begun shipping AURYXIA™ (ferric citrate) tablets to wholesalers in the U.S. Auryxia is approved for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

22 Dec 2014

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta Pharmaceuticals LLC, today announced that the Journal of Clinical Rheumatology published a comprehensive review of a post-hoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized Phase III trials and one open-label extension trial.

14 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

Research highlights potential of computers to enhance quality of care, medical outcomes

A computer system was more effective than doctors at collecting information about patient symptoms, producing reports that were more complete, organized and useful than narratives generated by physicians during office visits, according to a Cedars-Sinai study.

10 Dec 2014

At-home test sniffs out prodromal Parkinson’s disease

An at-home olfactory test helps to identify people with an increased risk of having dopamine transporter imaging indicative of early Parkinson’s disease, show data from the Parkinson Associated Risk Syndrome study.

9 Dec 2014

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Constipation News and Research

Latest Constipation News and Research

Added benefit of lurasidone drug not proven for schizophrenia

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Temple University Hospital participating in trial to test vibrating capsule for chronic constipation treatment

Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Nonmotor symptoms cluster in Parkinson’s disease patients

Disturbed gut microbiome linked to Parkinson’s disease

New research sheds light on the role of Sox10 protein in Hirschsprung's disease patients

FDA approves RYTARY for Parkinson's disease treatment

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Keryx Biopharmaceuticals supplies AURYXIA tablets to wholesalers in US

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Research highlights potential of computers to enhance quality of care, medical outcomes

At-home test sniffs out prodromal Parkinson’s disease

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Constipation News and Research

Latest Constipation News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in